New Nanotechnology for Triple Negative Breast Cancer
Multifunctional Nanotechnology Platform for Triple Negative Breast Cancer Treatment
This work aims to create tiny, smart delivery systems to bring powerful medicines directly to triple-negative breast cancer cells, hoping to improve treatment for patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Howard University NIH-funded |
| Lab location | 1 site (Washington, United States) |
| Project ID | NIH-11128818 on NIH RePORTER |
What this research studies
Triple-negative breast cancer can be aggressive and hard to treat, often leading to resistance to current therapies. This project focuses on developing special nanoparticles that can carry multiple chemotherapy drugs directly to cancer cells. By targeting the cancer more precisely, these nanoparticles could deliver higher doses of medicine while potentially reducing side effects on healthy tissues. The goal is to overcome drug resistance and improve the effectiveness of chemotherapy for patients with this challenging type of breast cancer.
Who could benefit from this research
Good fit: This research is ultimately aimed at patients diagnosed with triple-negative breast cancer, particularly younger women and those of African-American and Hispanic descent who are disproportionately affected.
Not a fit: Patients without triple-negative breast cancer or those whose cancer does not respond to the specific drugs delivered by these nanoparticles may not receive direct benefit from this particular approach.
Why it matters
Potential benefit: If successful, this new nanotechnology could lead to more effective treatments for triple-negative breast cancer, potentially reducing side effects and improving patient outcomes.
How similar studies have performed: While current chemotherapies and immunotherapies exist for TNBC, this approach of using multifunctional targeted nanoparticles for enhanced drug delivery represents a novel strategy to improve upon existing treatments.
Where this research is happening
Washington, United States
- Howard University — Washington, United States (Active)
Researchers
- Principal investigator: Akala, Emmanuel O — Howard University
- Study coordinator: Akala, Emmanuel O
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.